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Abstract
Background: After a spinal cord lesion, axon regeneration is inhibited by the presence of a diversity of inhibitory
molecules in the lesion environment. At and around the lesion site myelin-associated inhibitors, chondroitin sulfate
proteoglycans (CSPGs) and several axon guidance molecules, including all members of the secreted (class 3)
Semaphorins, are expressed. Interfering with multiple inhibitory signals could potentially enhance the previously
reported beneficial effects of blocking single molecules. RNA interference (RNAi) is a tool that can be used to
simultaneously silence expression of multiple genes. In this study we aimed to employ adeno-associated virus
(AAV) mediated expression of short hairpin RNAs (shRNAs) to target all Semaphorin class 3 signaling by knocking
down its receptors, Neuropilin 1 (Npn-1) and Neuropilin 2 (Npn-2).
Results: We have successfully generated shRNAs that knock down Npn-1 and Npn-2 in a neuronal cell line. We
detected substantial knockdown of Npn-2 mRNA when AAV5 viral vector particles expressing Npn-2 specific
shRNAs were injected in dorsal root ganglia (DRG) of the rat. Unexpectedly however, AAV1-mediated expression of
Npn-2 shRNAs and a control shRNA in the red nucleus resulted in an adverse tissue response and neuronal
degeneration. The observed toxicity was dose dependent and was not seen with control GFP expressing AAV
vectors, implicating the shRNAs as the causative toxic agents.
Conclusions: RNAi is a powerful tool to knock down Semaphorin receptor expression in neuronal cells in vitro and
in vivo. However, when shRNAs are expressed at high levels in CNS neurons, they trigger an adverse tissue
response leading to neuronal degradation.
Background
The lesion environment of the injured spinal cord con-
stitutes an impediment to regenerating axons [1-3]. A
number of neurite growth inhibitors expressed in and
around the lesion area have been identified, including
the myelin-associated inhibitors NogoA, myelin-
associated glycoprotein (MAG), oligodendrocyte myelin
glycoprotein (OMgp), EphrinB3 and Semaphorin4D as
well as scar-derived factors such as CSPGs, secreted
Semaphorins, Ephrins, Slits and Wnts (reviewed by Bols-
over et al., Harel and Strittmatter, and Giger et al [4-6]).
These proteins act through multimeric receptors
expressed at the surface of injured axons. Functional
interference with NogoA or its receptor stimulated the
recovery of function after spinal cord lesion [6]. Neutra-
lizing inhibitory molecules in the injured cord would be
an important component of a multifaceted therapeutic
strategy to promote axonal regeneration. Given the
diversity of repulsive proteins, targeting of multiple
ligands or their receptors will be required to produce
extensive repair after CNS trauma. RNAi is a relatively
new tool to silence gene expression in a sequence-speci-
fic manner. shRNAs can be used to simultaneously
silence the expression of multiple genes [7-10]. We
investigated whether this technology could be applied in
the CNS to render injured neurons insensitive to multi-
ple repulsive signals. As a first step in this direction we
explored the feasibility to apply RNAi to interfere with
the signaling of secreted chemorepulsive Semaphorins
in vivo.
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dance cues. Secreted Semaphorins are expressed by
meningeal fibroblasts invading the spinal cord lesion site
[11,12]. The receptor for secreted Semaphorins is com-
posed of a Semaphorin binding subunit (Neuropilin-1 or
Neuropilin-2) and a Plexin signaling subunit (reviewed
by Zhou et al. [13]). These receptors persist in corti-
cospinal tract and rubrospinal tract (RST) neurons after
injury [12,14]. Rubrospinal neurons express Npn-2 but
not Npn-1. The signaling component plexinA1 and the
intracellular signaling molecule CRMP2 are present in
rubrospinal neurons [12]. Following injury of the RST,
the expression of plexin A1 and A4 persist, whereas
plexin A2 is upregulated and A3 is undetectable in the
red nucleus [15]. Thus, this descending motor tract in
the spinal cord is potentially sensitive to Semaphorins in
the lesion core. Axon outgrowth is considerably
improved when neurons are cultured on Semaphorin3A
(Sema3A)-deficient meningeal cells [16] and axon cross-
ing from an astrocyte to a meningeal cell substrate is
enhanced by blocking Npn-2 [17]. Recently, an inhibitor
of Sema3A was successfully used to enhance regenera-
tion and to produce a certain degree of functional
recovery of the injured spinal cord [18]. Interfering with
Semaphorin-Neuropilin signaling would therefore be a
promising strategy to overcome inhibition of axonal
regeneration.
The potential of RNAi-based therapies as well as the
utility of RNAi for basic research is widely recognized.
A persistent question in the field of RNAi is how the
efficiency and specificity of RNAi-mediated knockdown
of gene expression can be improved. The development
of RNAi has been hampered by cellular toxicity, which
can be the result of interference with the endogenous
miRNA machinery, the induction of innate immune
responses, and off-target effects [19-24]. Here we docu-
ment our attempts to block Semaphorin receptor
expression by expressing shRNA molecules in neuronal
cells in vitro and in the red nucleus and DRG neurons
in vivo. We show that shRNA-mediated knockdown of
the Semaphorin receptor Npn-1 and Npn-2 can be
achieved in cultured neuronal cells by lentiviral vector
derived shRNAs. One of two shRNA sequences was
effective in AAV-mediated knockdown of Npn-2 in
DRG neurons in vivo. Unexpectedly, AAV1-mediated
expression of shRNAs in the red nucleus resulted in an
adverse tissue response and neuronal degeneration.
We conclude that, although this technology has great
potential to interfere with multiple inhibitory signaling
pathways, the present results illustrate unanticipated pro-
blems related to the in vivo delivery of shRNA. We discuss
a number of solutions that have to be implemented before
this technology can be routinely applied to interfere with
chemorepulsive signaling following neurotrauma.
Results
Efficient in vitro knockdown of Npn-1 and Npn-2 by
lentiviral delivery of shRNA
As a primary screening method to assess knockdown
efficiency of endogenous Npn-1 and Npn-2 expression
levels, F11 cells, a fusion cell line derived from of rat
embryonal DRG and mouse neuroblastoma cells [25],
were transduced with lentiviral vectors encoding green
fluorescent protein (GFP) and an shRNAs directed
against Npn-1 or Npn-2 (Figure 1a). Four days after
transduction, total RNA was isolated. QPCR analysis
revealed that Npn-1 expression after transduction with
two shRNA sequences was significantly reduced to
31.4 ± 1.8% and 17.5 ± 3.4% respectively (Figure 2a).
Western blot analysis confirmed Npn-1 knockdown at
the protein level by showing that expression was
reduced to 39.2 ± 9.7% and 5.7 ± 2.6% (Figure 2b,2d).
Two out of seven Npn-2 shRNA sequences successfully
reduced Npn-2 mRNA expression to 7.8 ± 1.1% and
13.3 ± 1.0% respectively (Figure 2c).
AAV1-mediated overexpression of shRNA in the red
nucleus results in a dose dependent adverse tissue
response and neuronal degeneration
Recent data from our lab has shown that lentiviral vec-
tors are suboptimal transducers of rubrospinal neurons.
The efficiency of transduction of red nucleus neurons is
much better when using AAV1 viral particles[26].
Therefore, the control shRNA and the two shRNA cas-
settes that were effective in knocking down Npn-2
expression in vitro were cloned in the pTR-CGW AAV2
backbone (Figure 1b). After packaging, the resulting
AAV1 particles mediate both GFP and shRNA expres-
sion. These vectors were stereotactically injected in the
red nucleus of rats. Animals were sacrificed 3 weeks
Figure 1 Schematic representation of lentiviral and adeno
associated constructs. All viral particles express green fluorescent
protein (GFP) under the cytomegalovirus (CMV) promoter flanked by
the Woodchuck hepatitis posttranscriptional regulatory element
(WPRE). In the lentiviral (LV) transfer vector (A) the shRNA expression
cassette, driven by the H1 RNA promoter (H1), is placed back to
back with the GFP expression cassette. In the adeno associated viral
vector (AAV) the shRNA expression cassette is placed upstream of
the CMV promoter (B). The packaging cassettes are flanked by
inverted terminal repeats (ITR) or long terminal repeats (LTR) for the
AAV and LV cassettes respectively.
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chemistry. GFP immunohistochemistry was detected in
the red nucleus, demonstrating efficient transduction
efficiency. However all animals injected with AAV1
shRNA vectors displayed neuronal degeneration and an
adverse tissue response (Figure 3a and 3a’) as compared
to the uninjected contralateral nucleus (Figure 3a and
3a“). High magnification photomicrographs consistently
showed atrophic morphology of neurons that were
transduced with an AAV1 vector encoding shRNA
( F i g u r e3 ba n d4 b ) .T h i sa d v e r s et i s s u er e s p o n s ea n d
aberrant cellular morphology was not present in AAV1-
GFP transduced neurons (Figure 3c and 4a), indicating
that the effect was not due to GFP overexpression or
AAV transduction per se.
The adverse tissue response was partially alleviated by
injecting a 10 fold lower viral titer (Figure 4c). Although
more neurons appear to survive under these conditions,
many still have an irregular and vacuolar morphology.
An alternative strategy to attenuate the level of trans-
gene expression in rubrospinal neurons is the use of
AAV2 particles. Previous experiments from our labora-
tory have shown that both spread and expression levels
are reduced when using AAV2 as compared to AAV1
vector particles[26]. When control shRNAs were
expressed by injection of AAV2 vectors in the red
nucleus, GFP immunohistochemistry showed a confined
population of GFP positive neurons within the red
nucleus (Figure 4d). As expected, AAV2 mediated GFP
expression was lower than the expression levels
observed in the AAV1 injected animals and no shRNA
induced adverse tissue response was present. However,
after injection of AAV2 expressing Npn-2 shRNAs, no
knockdown was observed under these conditions (not
shown).
AAV5 mediated knockdown of Npn-2 in rat dorsal root
ganglia
We also studied Npn-2 knockdown in a separate model
often used for neuroregeneration studies, the rat dorsal
root ganglia. Previous results showed that up to 80% of
the DRG sensory neurons can be readily transduced by
Figure 2 Efficient lentivirus mediated knockdown in F11 cells. F11 cells were infected with a lentiviral vector expressing GFP and a control
shRNA and a two shRNAs directed against Npn-1 or Npn-2. Two days after infection Npn-1 mRNA expression was reduced to 31.4 ± 1.8% and
17.5 ± 3.4% (mean ± SEM). Npn-2 expression was knocked down to 7.8 ± 1.1% and 13.3 ± 1.0% (mean ± SEM) (A). Western blot (D) and
quantification thereof (B) for Npn-1 showed a similar knockdown efficiency 39.2 ± 9.7% and 5.7 ± 2.6% (C) (mean ± SEM) (* <0.05, ** p < 0.005)
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We therefore packaged our Npn-2 targeting and control
shRNA vectors in AAV5 particles and injected this vec-
tor in the L4 and L5 DRG of 3 adult female Wistar rats.
Three weeks after injection Npn-2 expression was ana-
lyzed by in situ hybridization. In DRGs injected with
virus expressing the control shRNA 37.2 ± 6.6% of all
GFP positive cells expressed Npn-2 (Figure 5a,5b,5c,5g).
One of the two shRNA sequences was able to reduce
the proportion of Npn-2 expressing cells to 16.5% ± 5.0
(p < 0.05) while the second shRNA was not effective
(Figure 5d,5e,5f,5g). In contrast to the shRNA induced
toxicity and aberrant cell morphology observed in the
red nucleus, the DRG neurons appeared unaffected by
the expression of shRNAs.
Discussion
T h ea i mo ft h ep r e s e n ts t u d yw a st od e v e l o pa nR N A i
based strategy to knock down the expression of the
class-3 Semaphorin receptors Npn-1 and Npn-2 in neu-
rons of spinal nerve tracts and to employ this methodol-
ogy to investigate the proposed involvement of these
receptors in the failure of CNS-axons to regenerate. We
have successfully developed shRNAs that knock down
Figure 3 shRNA induced toxicity in the red nucleus. Transduction of the red nucleus with AAV1 particles expressing GFP and a control
shRNA (A, B) or GFP alone (C). Injection of AAV1 particles expressing GFP and a control shRNA results in a loss of rubrospinal motor neurons
and an infiltration of small diameter cells as shown in cresyl violet staining (A). Insets show enlargements of the injected (A’) and contralateral
side (A”). High magnification confocal microscopy images of GFP fluorescence show degenerating motor neurons (arrow heads) that were
transduced with an AAV1 vector encoding shRNA (B). These degenerating neurons are not present in AAV1-GFP transduced neurons (C).
Scalebar A’ and B: 50 μm
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line. In vivo, AAV5 mediated expression of the most
effective Npn-2 shRNA resulted in knockdown of Npn-2
in DRG sensory neurons. Unexpectedly, AAV5-mediated
expression of a second shRNA had no effect. AAV1-
mediated expression of a control shRNA and a Npn-2-
shRNA in the red nucleus resulted in an adverse tissue
response, including neuronal cell degeneration. These
observations demonstrate that, although this technology
would have great potential to interfere with multiple
chemorepulsive signaling pathways, unanticipated pro-
blems with cytotoxicity currently preclude the routine
use of this approach in studies on neural repair in vivo.
Selection of shRNAs for in vivo use
Despite considerable efforts to improve the selection of
effective RNAi target sequences, including the develop-
ment of various algorithms [28-30] and the use of
favourable thermodynamic properties [31,32], several
shRNA sequences against a particular target mRNA need
to be screened to obtain efficient knockdown. We initially
developed two shRNAs for Npn-1 and seven for Npn-2
and evaluated their capacity to silence Npn-1 or Npn-2
expression in F11 cells. Both Npn-1 and two out of seven
Npn-2 shRNAs exhibit potent gene silencing following
lentiviral vector-mediated delivery to the F11 cell line.
When using a standard transfection for shRNA expression,
most shRNA sequences are capable of reducing target
expression (our own observation, not shown). The
decreased effectiveness of lentiviral vector-mediated
knockdown could be due to significantly lower shRNA
expression levels as compared to an expression level
achieved using transfection methods. Standard transfec-
tion methods deliver several hundred thousand plasmid
molecules to one single cell resulting in fast-onset high
level expression of shRNAs. In contrast, when shRNAs are
Figure 4 Reduced toxicity by decreasing shRNA expression levels in the red nucleus. GFP expressing neurons in the red nucleus shows
normal morphology after injection with AAV1-GFP throughout the red nucleus (A). AAV1-shRNA injection results in profound neuronal
degeneration and only occasional GFP-positive profiles of transduced neurons are observed usually at some distance from the injection site
(arrow heads) (B). Lowering shRNA expression by reducing the injected AAV1 particles 10 fold (C) or using AAV2 particles (D) nearly completely
alleviates toxicity. Scale bar A: 50 μm
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Page 5 of 11Figure 5 AAV5 mediated knockdown of Npn-2 in DRG in vivo. AAV5 particles expressing GFP and a control shRNA (A, B, C) or shRNA
directed against Npn-2 (D, E, F) were injected in the L4 and L5 DRG of 3 adult female wistar rats. GFP immunoreactivity (green: A, B, D, E) and
Npn-2 mRNA (red: A, C, D, F) were visualized in the same section three weeks after AAV injection. A marked reduction in the percentage of Npn-
2 expressing cells among the GFP positive cells was observed after shRNA expression: 16.5 ± 5.0% versus 37.2 ± 6.6% in control animals (G)
(mean ± SEM, * p < 0.05). Scalebar A: 100 μm
Ehlert et al. BMC Neuroscience 2010, 11:20
http://www.biomedcentral.com/1471-2202/11/20
Page 6 of 11introduced by means of lentiviral delivery, the number of
genomic copies per cell is reduced by at least 3 orders of
magnitude. This would result in reduced shRNA expres-
sion levels and consequent diminished knockdown effi-
ciency of the target mRNA.
In vivo studies
The efficacy of the selected shRNAs was tested in two
neural systems that are widely used to study axonal
regeneration: the sensory neurons of the DRG and the
neurons of the red nucleus that form the rubrospinal
tract. Work from our laboratory has shown that, as
compared to AAV vectors, lentiviral vectors poorly
transduce sensory neurons in vivo[27] and are subopti-
mal transducers of rubrospinal neurons[26]. Therefore
the most effective shRNAs were expressed via AAV5
vectors in DRG and via AAV1 vectors in rubrospinal
neurons. We chose these two AAV serotypes because
we have shown that these are the most efficient AAV
serotype vectors for these two neuronal populations
[26,27].
Despite our preselection of the most effective shRNA
by lentiviral vector-mediated gene silencing in F11 cells,
only one of the two selected shRNAs was capable to sig-
nificantly reduce the population of Npn-2 expressing
DRG neurons. Although the observation that the second
shRNA is somewhat less effective in vitro may already
be an indication that it would be less capable to knock
down Npn-2 in vivo, these observations also demon-
strate that a shRNA that is effective in vitro not necessa-
rily works in vivo.
AAV1-mediated shRNA expression in the red nucleus
caused an unexpected adverse tissue reaction. Three
weeks after AAV1 injection, many of the rubrospinal
neurons contain vacuolar structures and have an
atrophic appearance. Furthermore, there is considerable
cell death as shown by the loss of neurons and the acel-
lular granular structure of the tissue at the site of AAV
injection. This phenomenon is unrelated to the shRNA
sequence used and is not seen after AAV1-mediated
GFP expression. It has been reported that saturating the
miRNA machinery by overexpressing shRNAs, inhibits
endogenous miRNA processing [22,23,33,34] with con-
comitant adverse effects on the transduced cells [21-24].
In the nucleus, exogenous shRNAs can saturate the
function of Exportin-5, a factor required for nuclear
export of pre-miRNAs and shRNAs [33-35]. This satura-
tion can be reversed by overexpression of Exportin-5
enhancing shRNA and endogenous miRNA activity in
vitro [34] and in vivo [22]. Exportin-5 expression is rela-
tively low in brain tissue [34] as compared to other tis-
sues, rendering the brain particularly sensitive to
Exportin-5 function saturation. Similarly, in the cyto-
plasm, saturating the endogenous RNA induced
silencing complex (RISC) may interfere with endogenous
RNAi. The observation that overexpression of the cata-
lytic RISC RNAse component Argonaut-2 enhances
shRNA activity [36] demonstrates that Argonaut-2 is a
rate limiting component in RNAi and is therefore prone
to saturation. The cytotoxic effects observed here fol-
lowing AAV1-mediated delivery of shRNAs to the red
nucleus appears very similar to the toxicity described
before [21-23]. Saturation of the endogenous miRNA
machinery may also underlie these adverse effects since
lowering the viral dose, and thus the shRNA expression
levels, reduced although not completely curtailed the
toxic effects.
Interestingly, no toxicity was observed after AAV5-
mediated delivery of shRNA to the DRG. This could be
explained by our observation that, in terms of GFP
expression level, AAV1-mediated expression in the red
nucleus outperforms AAV5-mediated expression in the
DRG. If the same holds true for shRNA expression
levels, the differential expression levels could explain the
difference in toxicity. Controlling the shRNA expression
level by means of viral vector dose[24], regulatable
promoters [37], tissue specific promoters [38] or the use
of miRNAs [21,23], will be important variables for
future study and in vivo application of shRNAs.
Conclusions
Our data shows that we were able to generate shRNA
sequences that efficiently knock down Npn-1 and Npn-
2 expression in a neuronal cell line using a lentiviral
vector delivery system. Substantial in vivo reduction of
Npn-2 expression was achieved by injection of AAV5-
shRNA in the DRG, without clear indication of cellular
toxicity. In contrast, AAV1 mediated shRNA expression
in the red nucleus triggered an adverse tissue response
leading to neuronal degeneration. This cellular toxicity
is likely due to high levels of shRNA expression result-
ing in saturation of the endogenous miRNA machinery,
and has to be resolved for this technique to be routinely
used in neurobiological studies.
Methods
Cloning and characterization of Npn-1 and Npn-2 shRNA
sequences
Oligonucleotides encoding shRNAs directed against Npn-
1 and Npn-2 (table 1) were cloned in the pRRLsinPPTh
lentiviral (LV) vector, expressing GFP under the cytome-
galovirus (CMV) promoter 3’ flanked by a Woodchuck
hepatitis posttranscriptional regulatory element (WPRE)
and a H1 RNA polymerase promoter expression cassette
(Figure 1a). As a control a shRNA lacking homology to
the rat transcriptome, targeting the Arabidopsis Thaliana
FUSA 5 gene, was generated (table 1). Viral particles were
packaged as described before [39] using the pMD2.G and
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duced with a multiplicity of infection (MOI) of 100. Four
days after transduction, protein and total RNA was iso-
lated and Neuropilin expression levels were determined by
qPCR analysis and Western Blot. The two most effective
shRNA sequences were cloned in an AAV vector plasmid
containing AAV2 inverted terminal repeats, a CMV-GFP
expression cassette 3’ flanked by a WPRE and a H1 RNA
polymerase promoter expression cassette (Figure 1b).
qPCR analysis
cDNA was synthesized using m-MLV reverse transcrip-
tase (Invitrogen) according to manufacturer’s guidelines
with 500 ng total RNA and random hexamers. Npn-1
and Npn-2 expression levels were determined by quanti-
tative PCR on an Applied Biosystems 7300 real-time PCR
system using SYBR green master mix (Applied Biosys-
tems) and 0.3 mM oligonucleotide (Eurogentec) (table 2).
Gapdh, Beta-actin and Ef1-alpha expression levels were
used to normalize the data for variations in cDNA input.
Western blot analysis
Cells were lysed in RIPA buffer (25 mM Tris-HCl, 150
mM NaCl, 1% Triton ×100, 1% Sodium Deoxycholate,
0.1% SDS pH 7.5). Samples were separated on 8% SDS-
PAGE and transferred to a nitrocellulose membrane
(Schleicher & Schuell). To detect endogenous Npn-1 a
goat anti-Npn-1 antibody (1:1000, AF566, R & D sys-
tems) was used. A mouse anti-Actin antibody (1:1000,
A5316, Sigma-Aldrich) was used to correct for variation
in gel loading. Bands were visualized and quantified
using an Odyssey Infrared Imaging Station (LI-COR)
using a donkey anti-mouse-IRDye800 antibody, donkey
anti-goat IRDye800 (both 1:4000, Rockland Immuno-
chemicals) or donkey anti-mouse-Cy5 (1:400, Jackson
ImmunoReseach)
Adeno-associated viral vector preparation
Ten 9.5 cm culture dishes (Greiner Bio-One) of
HEK293T cells were transfected with 50 μg AAV vector
plasmid and 150 μg packaging plasmid (pDG1, pDG2 or
pDG5 for AAV serotype 1, 2 or 5 respectively) [40]. The
cells were harvested in lysis buffer (50 mM Tris-HCl pH
8.5, 150 mM NaCl, 2 mM MgCl2,1% triton-×100) 72 hrs
after transfection and incubated with 10 μg/ml DNAse I
(Roche) for 1 hour. Cell lysates were cleared by centrifu-
gation at 3.200 RCF for 15 minutes and centrifuged on a
step gradient containing 60, 40, 25 and 15% iodixanol
(Axis Shield) for 1 h 10 m at 69.000 RPM in a Ti70
rotor (Beckman Coulter). The virus was recovered at
the 40-60% interface and concentrated in Dulbecco’s
phosphate buffered saline (D-PBS) with 5% sucrose
using a 100 kDa MWCO Amicon Ultra-15 centrifugal
device (Millipore). To determine the viral titer, viral
ssDNA was isolated by digesting the protein capsid with
Proteinase K (Roche) and purified using MageneSil Blue
beads (Promega) in SV RNA lysis buffer (Promega).
Viral titers were determined by qPCR using SYBR green
master mix (Applied Biosystems) and 0.3 mM primers
directed against the CMV promoter (table 2).
Experimental animals
A total of 42 adult female Wistar rats (225-250 g, Har-
lan) were used in this study. Animals were housed in
groups under standard conditions with food and water
ad libitum and a 12 h:12 h light/dark cycle. Experimen-
tal procedures were performed in accordance with the
committee for laboratory animal welfare and experi-
mentation of the Royal Netherlands Academy of
Sciences.
Table 1 shRNA targeting sequences
Gene Sequence
Npn-1
a cttcaacccacatttcgat
Npn-1
b gatagtaagaggtgtcatca
Npn-2 ggagtatctccaggtggac
Npn-2 gcccagccaggtgaagaat
Npn-2
a agattgtcctcaacttcaa
Npn-2 tggccggattgctaatgaa
Npn-2 catggagttccaataccaa
Npn-2 caaggagtatctccaggtgga
Npn-2
b caagcccagccaggtgaagaat
Fusa5 agatcctctgttctctctc
Targeting sequences in rat Neuropilin 1 (Npn-1) and rat Neuropilin 2 (Npn-2)
genes used to generate short interfering RNAs (shRNA).
(a,b) Sequences that
displayed efficient shRNA mediated knockdown of Npn-1 and Npn-2 in F11
cells when delivered by lentiviral vectors. The Arabidopsis Thaliana FUSA 5
gene (Fusa5) targeting sequence was used to create a non functional control
shRNA construct.
Table 2 Primers used for QPCR analysis
Gene AccNo Forward primer Reverse primer
Npn-1 NM_145098 ctgtgcaaaaccaacagacctagat gttcttgtcgcctttcccttct
Npn-2 NM_030869 tccggagagatttccatcga aaagccgagatgggttcca
Beta actin NM_031144 gctcctcctgagcgcaag catctgctggaaggtggaca
Gapdh NM_017008 tgcaccaccaactgcttagc ggcatggactgtggtcatga
Ef1 alpha NM_175838 accctccacttggtcgttttg agctcctgcagccttcttgtc
CMV promoter n.a. aatgggcggtaggcgtgta aggcgatctgacggttcactaa
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The experimental groups were composed as follows: Six
animals were injected with AAV1 expressing Npn-2
shRNA(a) (1.4 × 10
12 GC/ml), Npn-2 shRNA(b) (1.1 ×
10
12 GC/ml) or control shRNA (1.7 × 10
12 GC/ml). To
further study the dose dependent toxicity, 3 animals were
injected with 1 μl AAV1 expressing control shRNA (1.7 ×
10
12 and 1.7 × 10
11 GC/ml) or GFP only (1.7 × 10
12 GC/
ml). To assess toxicity induced by AAV2-mediated expres-
sion of shRNAs, 6 animals were injected with 1 μl AAV2
expressing control shRNA (6.0 × 10
11 GC/ml). Stereotaxic
injections were performed as described previously[41]
under deep anesthesia with an intramuscular injection of
Hypnorm (Fentanyl/Fluanisone, 0.08 ml/100 g, Janssen
Pharmaceuticals) and Dormicum (Midazolam, 0.02 ml/
100 g, Roche). The skull was exposed and a hole was
drilled to aid positioning of the needle. A glass needle was
lowered into the brain at A/P - 5.4; L+0.7; DV-6.6 from
bregma. 1 μl viral vector was infused at a rate of 0.2 μl/
min. Three weeks after vector injection animals were
euthanized by injecting an overdose of Nembutal (sodium
pentobarbital, Sanofi Sante) followed by transcardial perfu-
sion of sequentially ice cold saline and 4% paraformalde-
hyde (PFA) in 0.1 M phosphate buffer.
Injection of AAV5 in dorsal root ganglia
Per virus, three adult female Wistar rats were injected
with virus expressing control shRNA (2.2 × 10
12 GC/
ml), Npn-2 shRNA(a) (1.9 × 10
12 GC/ml) or Npn-2
shRNA(b) (3.9 × 10
12 GC/ml). Animals were deeply
anesthetized by an intramuscular injection of Hypnorm
(Fentanyl/Fluanisone, 0.08 ml/100 g, Janssen Pharma-
ceuticals) and Dormicum (Midazolam, 0.02 ml/100 g,
Roche). The muscles overlaying the lumbar vertebral
column were retracted and dorsal root ganglia at L4 and
L5 were exposed by a partial laminectomy. 1 μlv i r a l
vector was unilaterally injected in the L4 and L5 DRG
at a rate of 0.2 μl/min. Muscle layers were sutured and
the skin was closed with Michell clips (Fine science
tools). Three weeks after vector injection animals were
euthanized by injecting an overdose of Nembutal
(sodium pentobarbital, Sanofi Sante) followed by trans-
cardial perfusion of ice cold saline followed by 4% PFA
in 0.1 M phosphate-buffer.
Immunohistochemistry and In situ hybridization
After perfusion and dissection, tissue was post fixated in
4% PFA in P-buffer, incubated in 0.25 M EDTA/PBS
and cryoprotected in 25% sucrose/PBS. Tissue was
embedded in OCT compound (Sakura) and snap frozen
in 2-methylbutane. 20 μmC r y os e c t i o n sw e r ec u t ,
mounted on Superfrost Plus slides (Fischer scientific)
and stored at -80°C.
Immunohistochemistry staining for GFP was
performed by blocking sections for one hour in Tris
buffered saline (TBS) containing 0.4% Triton ×-100
and 5% fetal calf serum (FCS), followed by incubation
with rabbit anti-GFP (1:100, AB3080, Chemicon) for
1 6h o u r sa t4 ° C .A f t e r3w a s h e ss e c t i o n sw e r ei n c u -
bated with donkey anti rabbit-Biotin (1:400, DAKO)
for 3 hours in TBS, 5% FCS and 0.4% Triton-×100 fol-
lowed by streptavidin-Alexa488 (1:400, Invitrogen).
Fluorescent images were captured using a Zeiss
LSM510 confocal laser scanning miscroscope. To
visualise general brain histology, sections were counter
stained with cresy violet after which bright field
images were acquired using a Zeiss Axioplan
microscope.
In situ hybridization was performed using digoxi-
genin (DIG) labelled RNA probes transcribed from rat
Npn-2 cDNA as described before [42]. Antisense and
sense probes were generated by in vitro transcription
from linearized cDNA templates using T3 or T7 RNA
polymerase (Roche) and alkali-hydrolyzed to an aver-
age length of 200 nucleotides. Slides were post-fixed in
4% PFA in PBS, digested for 10 minutes with 10 μg/ml
Proteinase K (Boehringer Mannheim) in PBS contain-
ing 0.1% Triton-×100, post fixed for 15 minutes in 4%
PFA in PBS and acetylated for 10 minutes in 1%
triethanolamine containing 0.25% acetic anhydride.
Hybridization was performed for 16 hours at 60°C in
5×Denharts, 250 μg/ml yeast tRNA, 5×SSC and 50%
formamide. After stringency washes (all at 60°C, 5
minutes 5×SSC, 1 minute 2×SSC and 30 minutes
0.2×SSC, 50% formamide) slides were blocked in 1%
blocking reagent (Roche) and incubated for 16 hours
at 4°C with alkaline phosphatase conjugated anti-DIG
fab fragments (1:3000, Boehringer Mannheim) and
rabbit anti-GFP (1:100, AB3080, Chemicon) in 1%
blocking agent. Secondary antibody incubations were
preformed as described before. The anti-DIG antibody
was visualized by incubating with Fast Red (Sigma)
following manufacturers guidelines allowing color
development for 16 hours at room temperature. Fluor-
escent images were acquired using a Zeiss Axioplan2
microscope. An algorithm was designed in Image-Pro
plus (MediaCybernetics) to outline all GFP positive
neurons. Per DRG, all Npn-2 positive cells were
counted within this GFP positive cell population. For
each experimental group (n = 6 DRGs), the average
percentage of Npn-2 expression cells was calculated.
Statistical analysis
All results are expressed as mean ± SEM. Statistical sig-
nificance was tested with the student’s t-test. A value of
p < 0.05 was considered significant.
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